Pheochromocytoma: Evidence‑Based Diagnostic and Management Guidelines

Clinical Presentation

• The classic triad of episodic headaches, palpitations, and sweating has a diagnostic specificity of ≈90 % for pheochromocytoma in adults presenting with resistant hypertension【1】.
• Resistant hypertension (e.g., systolic ≥ 190 mm Hg despite high‑dose β‑blocker and ACE‑inhibitor therapy) is a hallmark manifestation of catecholamine‑secreting tumors【2】【3】.
• Facial flushing, intermittent pallor, tremor, unexplained weight loss, and nausea accompanying hypertensive spikes are common catecholamine‑excess features【4】【5】.
• Young adults with severe hypertension should prompt evaluation for secondary causes such as pheochromocytoma【6】.
• Physical findings of a displaced apical impulse (suggesting left‑ventricular hypertrophy) and persistent tachycardia despite β‑blockade indicate chronic catecholamine exposure and possible unopposed α‑adrenergic activity【1】.

Epidemiology & Natural History

• Autopsy series show that catecholamine‑producing tumors contributed to 55 % of deaths and were clinically unsuspected in 75 % of cases, underscoring frequent missed diagnoses【1】【3】.
• The mean interval from symptom onset to definitive diagnosis is ≈3 years; earlier recognition shortens this delay and improves outcomes【1】【3】.
• Approximately 95 % of patients experience paroxysmal symptoms, while ≈50 % have sustained hypertension between episodes【2】【3】.

Diagnostic Evaluation

• Plasma free metanephrines are the preferred initial screening test, offering 99 % sensitivity and 89 % specificity for pheochromocytoma【1】【3】.
• 24‑hour urinary fractionated metanephrines provide a sensitivity range of 77–97 % and specificity of 69–98 %; useful when plasma testing is unavailable【4】.
• Plasma metanephrine concentrations exceeding 3–4 × the upper reference limit are highly diagnostic【4】.
• Certain medications (tricyclic antidepressants, decongestants, amphetamines, reserpine, phenoxybenzamine) can cause false‑positive results and should be discontinued before biochemical testing【4】.
• Positive biochemical results warrant referral to a specialized hypertension center for confirmatory imaging and multidisciplinary management【5】【7】.

Differential Diagnosis (Key Points)

Management & Safety Considerations

• Beta‑blocker monotherapy (e.g., metoprolol) in the presence of untreated pheochromocytoma is potentially hazardous because it may precipitate unopposed α‑adrenergic stimulation and hypertensive crisis【4】.
• Pre‑operative α‑blockade (e.g., phenoxybenzamine) is mandatory before any surgical resection to control blood pressure and prevent intra‑operative catecholamine surges【4】.
• Glucagon stimulation testing, if required for borderline biochemical results, should only be performed after adequate α‑blockade has been achieved【6】.

Recommended Clinical Pathway (Evidence‑Based)

All statements are derived from peer‑reviewed evidence with citation identifiers as indicated.

Physical Examination Findings in Pheochromocytoma

Vital Sign Abnormalities

Cardiovascular Examination

Dermatologic & General Appearance

Body Habitus & Weight

Syndromic Features to Assess

Clinical Caveats

Guideline Summary for Headache in Pheochromocytoma

Pathophysiology

• Episodic surges of catecholamines (norepinephrine and epinephrine) cause acute hypertensive spikes, cerebral vasoconstriction followed by reactive vasodilation, and thereby generate the characteristic severe, episodic headache pattern. 14
• Paroxysmal catecholamine release leads to sudden blood‑pressure spikes; approximately 95 % of patients experience paroxysmal symptoms and about 50 % have sustained hypertension between episodes. 14
• Higher norepinephrine secretion is directly associated with greater blood‑pressure variability and more pronounced sustained hypertension, intensifying headache risk. 14
• Increased blood‑pressure variability itself is an independent cardiovascular risk factor that contributes to headache generation. 14

Clinical Presentation

• The classic triad of episodic headache, palpitations, and sweating provides ≈ 90 % diagnostic specificity for pheochromocytoma in adults with resistant hypertension. 14
• Between 31 % and 40 % of patients with biochemically confirmed pheochromocytoma report headache as a presenting symptom. 14

Diagnostic Recommendations

• In any patient presenting with the classic triad or resistant hypertension, screen with plasma free metanephrines; this test shows ≈ 99 % sensitivity and ≈ 89 % specificity. 14
• Do not rule out pheochromocytoma solely because blood pressure is normal; catecholamine excess can provoke headache without sustained hypertension. 14
• The average diagnostic delay from symptom onset is about 3 years, and autopsy series indicate that ≈ 75 % of cases were clinically unsuspected before death. 14

Pre‑operative Management

• Initiate α‑adrenergic blockade (phenoxybenzamine or doxazosin) for 1–3 weeks before surgical resection; α‑blockade is mandatory to prevent intra‑operative hypertensive crises. 15

Surgical Treatment

• Laparoscopic adrenalectomy is the preferred approach for most adrenal pheochromocytomas, offering reduced postoperative pain, shorter hospital stay, and lower morbidity compared with open surgery. 15